CEO Daniel Barber Continues Routine Sell‑Offs at AQUESTIVE THERAPEUTICS Inc.
CEO Daniel Barber’s July 2026 AQUESTIVE THERAPEUTICS sell‑off shows routine liquidity management amid a sliding stock, not a bearish warning.
3 minutes to read
AQUESTIVE THERAPEUTICS INC
AQUESTIVE THERAPEUTICS Director Executes Routine 10(b)(5)(1) Buy‑Sell, Maintaining Long‑Term Stake Amid Rally
Julie Krop’s 10(b)(5)(1) buy‑sell move shows disciplined liquidity management and long‑term confidence in AQUESTIVE’s CNS therapeutics pipeline.
3 minutes to read
CEO of Aquestive Therapeutics Continues Moderate-Size Share Sales Amid Positive Pipeline Outlook, June 15 Insider Trade Adds 25,000 Shares at $4.16
CEO Barber Daniel sells 25k shares of AQT at $4.16 – insider trades hint at liquidity needs but long‑term confidence in this biotech’s pipeline.
3 minutes to read
AQUESTIVE THERAPEUTICS INSIDERS BUY 50K OPTIONS, SIGNALING BIG MOVE ON CNS DRUG RACE
Insider buying spurs bullish outlook for Aquestive, with senior execs securing 50,500 stock options—signaling confidence in the company’s CNS pipeline and future growth prospects.
3 minutes to read
Insider Sell‑Offs at Aquestive Therapeutics: Corporate Secretary Offloads 135,690 Shares Amid Quiet Executive Shake‑Up
Insightful insider sales at Aquestive Therapeutics reveal routine equity management, yet the company’s bullish pipeline and 89.5% YTD rally signal cautious optimism for investors.
3 minutes to read